The molecular chaperone Hsp90 is an exciting cancer drug target. The first Hsp90 inhibitor to enter clinical trials--the geldanamycin derivative 17AAG--has recently demonstrated proof-of-concept for successful target modulation, with sighs of therapeutic benefit. An important property of Hsp90 inhibitors is their ability to cause simultaneous, combinatorial blockade of multiple cancer-causing pathways by promoting the degradation of many oncogenic client proteins. However, the reason for therapeutic selectivity in cancer cells versus normal cells is unclear. New research now shows that Hsp90 exists in cancer cells in a heightened, activated state that is highly susceptible to inhibition by 17AAG.

中文翻译：

---

改变状态：选择性地给Hsp90癌症分子加药。

分子伴侣Hsp90是令人兴奋的抗癌药物。最近第一个进入临床试验的Hsp90抑制剂-格尔德霉素衍生物17AAG-已证明成功进行靶标调控的概念证明，并具有治疗效果。Hsp90抑制剂的重要特性是它们能够通过促进许多致癌性客体蛋白的降解而引起多种致癌途径的同时组合阻断。但是，尚不清楚癌细胞相对于正常细胞具有治疗选择性的原因。现在的新研究表明，Hsp90以高度活化的状态存在于癌细胞中，极易受到17AAG的抑制。